Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the North India cohort of the A1chieve study.
Indian J Endocrinol Metab
; 17(Suppl 2): S491-5, 2013 Nov.
Article
em En
| MEDLINE
| ID: mdl-24404489
ABSTRACT
BACKGROUND:
The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. MATERIALS ANDMETHODS:
Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from North India.RESULTS:
A total of 4912 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Patients had started on or were switched to biphasic insulin aspart (n = 3619), insulin detemir (n = 880), insulin aspart (n = 331), basal insulin plus insulin aspart (n = 37) and other insulin combinations (n = 44). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c 9.8%) and insulin user (mean HbA1c 9.8%) groups. After 24 weeks of treatment, both the study groups showed improvement in HbA1c (insulin naïve -2.7%, insulin users -2.6%). SADRs including major hypoglycaemic events or episodes did not occur in any of the study patients.CONCLUSION:
Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Tipo de estudo:
Clinical_trials
/
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Indian J Endocrinol Metab
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Índia